🇺🇸 Gbt021601 in United States

Gbt021601 (gbt021601) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Pricing & reimbursement

Gbt021601 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Rare Disease approved in United States

Frequently asked questions

Is Gbt021601 approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Gbt021601 in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.

What does Gbt021601 cost in United States?

annual_list: USD 80000.00 per year. Final patient cost depends on reimbursement and any patient access scheme.